Literature DB >> 14455084

The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox.

C H KEMPE, C BOWLES, G MEIKLEJOHN, T O BERGE, L ST VINCENT, B V BABU, S GOVINDARAJAN, N R RATNAKANNAN, A W DOWNIE, V R MURTHY.   

Abstract

This paper records an attempt to assess the prophylactic value of immune gamma-globulin, prepared from the serum of recently vaccinated adults, in the protection of close contacts of smallpox in Madras. The results serve to confirm findings of a previous study made in Madras in 1953, and show that the incidence of smallpox in close contacts given immune gamma-globulin prophylactically was about a quarter of that in the control contacts who received no such passive immunization-a statistically significant difference. Because of the limited supply of immune gamma-globulin, it is likely that its prophylactic use will be restricted to those especially at risk, for example, close unvaccinated family contacts, newborn infants and pregnant women.

Entities:  

Keywords:  GAMMA GLOBULIN; SMALLPOX/immunology

Mesh:

Substances:

Year:  1961        PMID: 14455084      PMCID: PMC2555541     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  2 in total

1.  Studies smallpox and complications of smallpox vaccination.

Authors:  C H KEMPE
Journal:  Pediatrics       Date:  1960-08       Impact factor: 7.124

2.  Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy.

Authors:  C H KEMPE; T O BERGE; B ENGLAND
Journal:  Pediatrics       Date:  1956-08       Impact factor: 7.124

  2 in total
  27 in total

1.  Antiviral immunity following smallpox virus infection: a case-control study.

Authors:  Erika Hammarlund; Matthew W Lewis; Jon M Hanifin; Motomi Mori; Caroline W Koudelka; Mark K Slifka
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

Review 2.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  SMALLPOX CHEMOPROPHYLAXIS.

Authors:  G YOUNG; G A FATTAL
Journal:  Can Med Assoc J       Date:  1963-10-05       Impact factor: 8.262

4.  The immune response to infection with vaccinia virus in mice. I. Infection and the production of antibody neutralizing cell-associated and cell-free virus.

Authors:  L M Hutt
Journal:  J Hyg (Lond)       Date:  1975-06

5.  Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment.

Authors:  Erika Hammarlund; Matthew W Lewis; Jon M Hanifin; Eric L Simpson; Nichole E Carlson; Mark K Slifka
Journal:  Vaccine       Date:  2007-11-29       Impact factor: 3.641

Review 6.  Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity.

Authors:  M K Slifka; R Ahmed
Journal:  Trends Microbiol       Date:  1996-10       Impact factor: 17.079

7.  [Can protection against smallpox be achieved with vaccina antigen? (Also a contribution on the standardization of vaccinia antigens].

Authors:  H Stickl
Journal:  Klin Wochenschr       Date:  1968-07-01

8.  Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.

Authors:  D Huw Davies; Megan M McCausland; Conrad Valdez; Devan Huynh; Jenny E Hernandez; Yunxiang Mu; Siddiqua Hirst; Luis Villarreal; Philip L Felgner; Shane Crotty
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 9.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

10.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.